3BUXTON M J, DRUMMOND MF, van HOUT BA, et al. Modelling in economic evaluation : an unavoidable fact of life[J]. Health Econ, 1997, 6(3): 217-227.
4EDDY DM. Technology assessment: the role of mathematical modellin[M]//MOSTELLER F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144- 153.
6SONNENBERG FA, BECK JR. Markov models in medical decision making: a practical guide [J]. Med Decis Making, 1993, 13(4): 322-338.
7Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analysis [M]. Canberra: Australian Government Publishing Service, 2002: 39.
8DRUMMOND MF, JEFFERSON TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ [J]. BMJ, 1996, 313(7052): 275-283.
9Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of pharmaceuticals: Canada[M]. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment(CCOHTA), 1997: 47.
10O'BRIEN B J, BRIGGS AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods[J]. Stat Methods Med Res, 2002, 11 (6): 455-468.
